Prevalence of Cerebral Small Vessel Disease in HIV Infected Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

655 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cerebral small vessel disease (CSVD) is a major cause of cognitive impairment and disability in the general population, secondary to the accumulation of asymptomatic elementary lesions. CSVD is directly correlated with age and cardiovascular risk factors and therefore would be challenging in term of public health care in the future. While HIV patients share the same cardiovascular risk factors and they are often diagnosed with cognitive impairment and frailty, CSVD has not been yet described in this population.

The global aim is to compare the prevalence of CSVD in a well controlled HIV+ population compared to HIV- controls matched with age and sex.

500 HIV+ patients and 250 age- and sex- matched controls will undergo a screening of the CSVD with a 10 minutes MRI (FLAIR and T2\*).

Prevalence of the CSVD will be compared between HIV+ patients and controls. General and HIV-specific parameters from their electronic medical records will be compared between HIV+/CSVD+ and HIV+/CSVD- patients.

We are expecting to prove that CSVD is more frequent in HIV+ population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study

NCT02592174

HIV-1 Infection

COMPLETED NA

COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old

NCT03268109

Memory Impairment HIV/AIDS Cognitive Impairment

COMPLETED

Does Micro-albuminuria is a Predictive Factor for Cognitive Impairment in Persons Living With HIV (PLHIV) Who Achieve cART-sustained Immunovirological Control ?

NCT02852772

HIV

COMPLETED

Prognosis of a First-Ever Stroke in Persons Living With HIV

NCT02748252

Cerebrovascular Accident, Acute HIV

TERMINATED

Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1

NCT00476671

HIV Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Seropositivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients

HIV infected for more than 5 years, aged over 50, treated with ARV

No interventions assigned to this group

control

non HIV (matched for age and gender)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age over 50
* chronic HIV seropositive patient infected for at least 5 years
* treated with any antiretroviral (ARV) therapy
* plasmatic HIV viral load \<40 copies/ml for at least one year with one authorized blip \< 1000 copies/ml per year

Exclusion Criteria

* co-infection with hepatitis C virus (HCV)
* uncontrolled high blood pressure (WHO criteria)
* Personal history of cerebral infarction or cerebral ischemia
* Personal history of neurological complication of the HIV-infection
* Use of illegal drugs (except cannabis or poppers)
* Glomerular filtration rate \< 15 mL/mn
* Complicated diabetes mellitus (glomerular filtration rate \< 60ml/mn and/or proteinuria\> 300 mg and/or retinopathy)

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No